Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
MBCCOP-Our Lady of Mercy Cancer Center
mi
from
Bronx, NY
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
MBCCOP-Our Lady of Mercy Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University
mi
from
Cleveland, OH
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University
mi
from
Cleveland, OH
Click here to add this to my saved trials
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
MetroHealth's Cancer Care Center at MetroHealth Medical Center
mi
from
Cleveland, OH
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
MetroHealth's Cancer Care Center at MetroHealth Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
High Dose Cyclophosphamide for the Treatment of Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
High Dose Cyclophosphamide for the Treatment of Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Sequential Compression Devices Effect on Fibrinolysis in Plastic Surgery Outpatients
The Effect of Intraoperative Sequential Compression Devices on Fibrinolysis in Plastic Surgery Outpatients: A Randomized Trial
Status: Enrolling
Updated:  12/31/1969
Swanson Center
mi
from
Leawood, KA
Sequential Compression Devices Effect on Fibrinolysis in Plastic Surgery Outpatients
The Effect of Intraoperative Sequential Compression Devices on Fibrinolysis in Plastic Surgery Outpatients: A Randomized Trial
Status: Enrolling
Updated: 12/31/1969
Swanson Center
mi
from
Leawood, KA
Click here to add this to my saved trials
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
The Effect of Antibiotic Administration on Blood Culture Positivity in Patients With Severe Sepsis and Septic Shock: a Prospective Multicenter Observational Trial.
Status: Enrolling
Updated:  12/31/1969
Maricopa Integrated Health Center
mi
from
Phoenix, AZ
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
The Effect of Antibiotic Administration on Blood Culture Positivity in Patients With Severe Sepsis and Septic Shock: a Prospective Multicenter Observational Trial.
Status: Enrolling
Updated: 12/31/1969
Maricopa Integrated Health Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
The Effect of Antibiotic Administration on Blood Culture Positivity in Patients With Severe Sepsis and Septic Shock: a Prospective Multicenter Observational Trial.
Status: Enrolling
Updated:  12/31/1969
Lions Gate Hospital
mi
from
North Vancouver,
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
The Effect of Antibiotic Administration on Blood Culture Positivity in Patients With Severe Sepsis and Septic Shock: a Prospective Multicenter Observational Trial.
Status: Enrolling
Updated: 12/31/1969
Lions Gate Hospital
mi
from
North Vancouver,
Click here to add this to my saved trials
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone With or Without Venetoclax in Relapsed/Refractory Multiple Myeloma With Assessment for t(11;14) Status
Status: Enrolling
Updated:  12/31/1969
Aurora Cancer Care-Milwaukee West
mi
from
Wauwatosa, WI
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone With or Without Venetoclax in Relapsed/Refractory Multiple Myeloma With Assessment for t(11;14) Status
Status: Enrolling
Updated: 12/31/1969
Aurora Cancer Care-Milwaukee West
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone With or Without Venetoclax in Relapsed/Refractory Multiple Myeloma With Assessment for t(11;14) Status
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone With or Without Venetoclax in Relapsed/Refractory Multiple Myeloma With Assessment for t(11;14) Status
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma
Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells
Status: Enrolling
Updated:  12/31/1969
Greenbaum Cancer Center
mi
from
Baltimore, MD
Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma
Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells
Status: Enrolling
Updated: 12/31/1969
Greenbaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma
Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma
Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma
Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma
Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma
Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma
Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma
Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma
Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma
Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma
Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma
Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Marshfield Medical Center-Marshfield
mi
from
Marshfield, WI
Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma
Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Marshfield
mi
from
Marshfield, WI
Click here to add this to my saved trials
Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma
Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Aurora Cancer Care-Milwaukee West
mi
from
Wauwatosa, WI
Daratumumab and Dexamethasone With Pomalidomide or Carfilzomib in Treating Patients With Relapsed Multiple Myeloma
Randomized Phase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Aurora Cancer Care-Milwaukee West
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia
Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia
Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
A PHASE I TRIAL OF SUBCUTANEOUS, OUTPATIENT INTERLEUKIN-2 FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
A PHASE I TRIAL OF SUBCUTANEOUS, OUTPATIENT INTERLEUKIN-2 FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Morristown, NJ
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Durham, NC
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers
Transplantation of Expanded and Unexpanded Umbilical Cord Blood Units Following Myeloablative Chemotherapy for Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers
Transplantation of Expanded and Unexpanded Umbilical Cord Blood Units Following Myeloablative Chemotherapy for Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Charles White, MD
mi
from
Mobile, AL
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Charles White, MD
mi
from
Mobile, AL
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Douglas Young, MD
mi
from
Fair Oaks, CA
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Douglas Young, MD
mi
from
Fair Oaks, CA
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Rodney Anderson, MD
mi
from
Stanford, CA
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Rodney Anderson, MD
mi
from
Stanford, CA
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Eugene Dula, MD
mi
from
Van Nuys, CA
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Eugene Dula, MD
mi
from
Van Nuys, CA
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Joel Kaufman, MD
mi
from
Aurora, CO
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Joel Kaufman, MD
mi
from
Aurora, CO
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Donald Bergner, MD
mi
from
Clearwater, FL
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Donald Bergner, MD
mi
from
Clearwater, FL
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Ira Klimberg, MD
mi
from
Ocala, FL
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Ira Klimberg, MD
mi
from
Ocala, FL
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Gary Friedlander, MD
mi
from
Rockville, MD
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Gary Friedlander, MD
mi
from
Rockville, MD
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Sheldon Freedman, MD
mi
from
Las Vegas, NV
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Sheldon Freedman, MD
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Edward Loizides, MD
mi
from
Bay Shore, NY
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Edward Loizides, MD
mi
from
Bay Shore, NY
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Richard Landau, MD
mi
from
Sellersville, PA
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Richard Landau, MD
mi
from
Sellersville, PA
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
H. Pat Hezmall, MD
mi
from
Fort Worth, TX
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
H. Pat Hezmall, MD
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Michael Godschalk, MD
mi
from
Richmond, VA
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Michael Godschalk, MD
mi
from
Richmond, VA
Click here to add this to my saved trials
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  6/23/2005
Roger Fincher, MD
mi
from
Spokane, WA
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 6/23/2005
Roger Fincher, MD
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Status: Enrolling
Updated:  6/23/2005
Hematology and Oncology Specialists
mi
from
Metairie, LA
Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Status: Enrolling
Updated: 6/23/2005
Hematology and Oncology Specialists
mi
from
Metairie, LA
Click here to add this to my saved trials
Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.
Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements for Pediatric Patients on Anticoagulation Therapy.
Status: Enrolling
Updated:  2/6/2006
University of Rochester Strong Medical Center
mi
from
Rochester, NY
Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.
Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements for Pediatric Patients on Anticoagulation Therapy.
Status: Enrolling
Updated: 2/6/2006
University of Rochester Strong Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Hemofiltration for Respiratory Failure After Bone Marrow Transplantation
Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  12/1/2006
Children's Hospital and Research Center
mi
from
Oakland, CA
Hemofiltration for Respiratory Failure After Bone Marrow Transplantation
Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 12/1/2006
Children's Hospital and Research Center
mi
from
Oakland, CA
Click here to add this to my saved trials
Hemofiltration for Respiratory Failure After Bone Marrow Transplantation
Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  12/1/2006
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Hemofiltration for Respiratory Failure After Bone Marrow Transplantation
Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 12/1/2006
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hemofiltration for Respiratory Failure After Bone Marrow Transplantation
Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  12/1/2006
Duke University
mi
from
Durham, NC
Hemofiltration for Respiratory Failure After Bone Marrow Transplantation
Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 12/1/2006
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Hemofiltration for Respiratory Failure After Bone Marrow Transplantation
Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  12/1/2006
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Hemofiltration for Respiratory Failure After Bone Marrow Transplantation
Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 12/1/2006
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase II Study of MS-275, in Combination With GM-CSF Treating Relapsed and Refractory Myeloid Malignancies
A Phase II Study of an Oral Histone Deacetylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies
Status: Enrolling
Updated:  4/25/2007
Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
A Phase II Study of MS-275, in Combination With GM-CSF Treating Relapsed and Refractory Myeloid Malignancies
A Phase II Study of an Oral Histone Deacetylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies
Status: Enrolling
Updated: 4/25/2007
Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Stent vs. Angioplasty for Treatment of Thrombosed AV Grafts: Long-Term Outcomes
Stent vs. Angioplasty for Treatment of Thrombosed AV Grfats: Long-Term Outcomes
Status: Enrolling
Updated:  5/21/2008
University of Alabama Hospitals
mi
from
Birmingham, AL
Stent vs. Angioplasty for Treatment of Thrombosed AV Grafts: Long-Term Outcomes
Stent vs. Angioplasty for Treatment of Thrombosed AV Grfats: Long-Term Outcomes
Status: Enrolling
Updated: 5/21/2008
University of Alabama Hospitals
mi
from
Birmingham, AL
Click here to add this to my saved trials
Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy
A Phase II Trial With Azacitidine Single Agent in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Who Are Ineligible for Standard Induction Therapy: A Department of Veterans Affairs Multi-Site Study
Status: Enrolling
Updated:  8/5/2008
Kansas City Veterans Affairs Medical Center
mi
from
Kansas City, MO
Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy
A Phase II Trial With Azacitidine Single Agent in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Who Are Ineligible for Standard Induction Therapy: A Department of Veterans Affairs Multi-Site Study
Status: Enrolling
Updated: 8/5/2008
Kansas City Veterans Affairs Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials